Houlihan Lokey is in a sustained downtrend, with the shares down 37.24% over the past year and 28.34% year-to-date, a stark underperformance versus the S&P 500's +15.01% one-year and +12.86% YTD gains. At $126.37, the stock is trading at just 15.3% of its 52-week range (52-week low of $112.83, high of $205.36), positioning it deep in the lower quartile of its annual band — a zone that historically signals either capitulation-style value or an ongoing falling-knife dynamic, and the persistent negative relative strength (-52.25% vs. SPY over one year) argues the latter remains the operative risk. The maximum drawdown of -41.02% confirms the severity of the de-rating, and with the stock sitting roughly 38% below its 52-week high, overhead supply from trapped holders is likely to cap rallies until a base forms.\n\nShort-term momentum remains weak and, critically, is deteriorating rather than stabilizing: the stock is down 5.13% over the past month and 9.83% over three months, with the one-month relative strength of -5.72% versus SPY indicating continued market-share loss even as the broader tape grinds higher. The one-month decline (-5.13%) is shallower than the three-month decline (-9.83%), suggesting the pace of selling has moderated somewhat, but the absence of a positive inflection — combined with the 6-month change of -10.58% — points to a persistent grind lower rather than a clean mean-reversion setup. Volume of roughly 600,808 shares on the latest session is unremarkable, offering no evidence of climactic selling or accumulation, and with no RSI data provided, the price action alone suggests momentum is decelerating but not yet reversing.\n\nKey technical levels are well defined: support sits at the 52-week low of $112.83, roughly 10.7% below the current $126.37 price, while resistance is anchored at the 52-week high of $205.36, some 62.5% above — a remarkably wide band that speaks to the violence of the trend reversal. A breakdown below $112.83 would likely trigger momentum-driven selling and open the door to new multi-year lows, whereas a reclaim of the $140–145 area (the July consolidation shelf) would be the first credible sign of a bottoming process. The beta of 0.967 indicates the stock moves roughly in line with the market, so the -52.25% one-year relative strength gap is driven by idiosyncratic, company-specific de-rating rather than leverage to market beta — meaning position sizing should account for the fact that this is a fundamentally driven drawdown, not a high-beta proxy play.

Houlihan Lokey's revenue trajectory has inflected sharply negative: the most recent quarter (period ending 2026-06-30) delivered $511 million in revenue, down 15.59% year-over-year from $605.3 million in the comparable prior-year quarter, a marked deceleration from the sequential cadence of $635.6 million (Q4), $717.1 million (Q3), and $659.5 million (Q2). The segment mix shows Corporate Finance at $303 million, Financial Restructuring at $119 million, and Financial Advisory Services at $89 million, with the Corporate Finance franchise — historically the growth engine — bearing the brunt of the cyclical M&A slowdown. This revenue contraction is the single most important driver of the stock's de-rating, as it undermines the multi-year compounding narrative that supported a premium multiple; the key question for investors is whether the trough in advisory activity is near, given restructuring's countercyclical offset remains a partial hedge.\n\nProfitability remains solid in absolute terms but is compressing: net income of $78 million in the latest quarter translated to a 15.26% net margin, down from 16.11% in the prior-year quarter and well below the 16.25% and 16.95% net margins posted in the two preceding quarters. Gross margin of 98.37% (per valuation data) reflects the asset-light, human-capital nature of advisory, but the quarterly income statement shows a 30.72% gross profit ratio with operating income of $78 million and an operating margin of 23.63% — healthy for the industry but trending lower as revenue declines outpace the firm's ability to flex compensation costs. EBITDA of $86 million in the quarter (16.83% EBITDA margin) versus $144.2 million a year ago underscores the operating deleverage, and the EPS of $1.17 (diluted $1.15) represents a meaningful step down from the $1.42–$1.47 range of the prior-year period.\n\nThe balance sheet is a genuine strength: debt-to-equity of just 0.21, a current ratio of 1.53, and $749 million in cash at period end provide substantial financial flexibility, while ROE of 18.17% and ROA of 11.17% remain respectable for the sector. However, cash flow quality has deteriorated sharply — trailing-twelve-month free cash flow of $484.6 million masks a -$342 million FCF quarter driven by a -$477 million working capital swing (largely receivables and bonus-related payables timing), and the PCF ratio of 13.57 reflects the market's discounting of this volatility. The company continues to return capital with $61 million in dividends paid and $50 million in buybacks in the quarter, but the negative operating cash flow of -$336 million means these distributions were funded from the balance sheet, a dynamic that is sustainable for a few quarters but not indefinitely if the revenue trough extends.